Clinical Trial Update: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating sacituzumab tirumotecan in combination with pembrolizumab as first-line maintenance therapy for cervical cancer and is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer | Phase 3 | Status: RECRUITING